Original Article

You have full text access to this OnlineOpen article

Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes

  1. Anne Proven†,
  2. Sherine E. Gabriel,
  3. Carlos Orces‡,
  4. W. Michael O'Fallon,
  5. Gene G. Hunder*

Article first published online: 7 OCT 2003

DOI: 10.1002/art.11388

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 49, Issue 5, pages 703–708, 15 October 2003

Additional Information

How to Cite

Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M. and Hunder, G. G. (2003), Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis & Rheumatism, 49: 703–708. doi: 10.1002/art.11388

Author Information

  1. Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  1. †

    Martina Hansens Hospital, Baerum Postterminal, Norway

  2. ‡

    University of Texas Health Science Center, San Antonio, Texas

*Mayo Clinic and Mayo Foundation, 200 First Street, SW, Rochester, MN 55905

Publication History

  1. Issue published online: 7 OCT 2003
  2. Article first published online: 7 OCT 2003
  3. Manuscript Accepted: 28 AUG 2002
  4. Manuscript Received: 13 MAY 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (72K)

REFERENCES

  • 1
    Frantzen P, Sutinen S, von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 1992; 19: 273–80.
  • 2
    Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in cyclic pattern. Ann Intern Med 1995; 123: 192–4.
  • 3
    Gran JT, Mykelbust G. The incidence of polymyalgia rheumatica and temporal arteritis in county of Aust Agder, Suth Norway: a prospective study 1987–1994. J Rheumatol 1997; 24: 1739–43.
  • 4
    Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806–12.
  • 5
    Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995; 24: 422–31.
  • 6
    Gabriel SE, O'Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93–6.
  • 7
    Hunder GG. Giant cell arteritis and polymyalgia rheumatica. Med Clin North Am 1997; 81: 195–219.
  • 8
    Myles AB, Perera T, Ridley MG. Prevention of blindness in giant cell arteritis by corticosteroid treatment. Br J Rheumatol 1992; 31: 103–5.
  • 9
    Delecoeuillerie G, Joly P, Cohen de Lara A, Paolagggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11year survey of 210 patients). Ann Rheum Dis 1988; 47: 733–9.
  • 10
    Kyle V, Hazelman B. Treatment of polymyalgia rheumatica and giant cell arteritis: steroid regimen in the first two months. Ann Rheum Dis 1989; 48: 658–61.
  • 11
    Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17: 1340–5.
  • 12
    Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041–8.
    Direct Link:
  • 13
    Andersson R, Malmvall, BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986; 220: 465–9.
    Direct Link:
  • 14
    Healey LA. Relation of giant cell arteritis to PMR. Bailliere's Clin Rheumatol 1991; 5: 371–8.
  • 15
    Gabriel S, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997; 40: 1873–8.
    Direct Link:
  • 16
    Pearce G, Ryan PFJ, Delmas PD, Tabensky DA, Seemen E. The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol 1998; 37: 292–9.
  • 17
    Melton LJ. History of the Rochester Epidemiology Project. Mayo Clinic Proc 1996; 71: 266–74.
  • 18
    Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–8.
    Direct Link:
  • 19
    Salvarni C, Gabriel SE, O'Fallon WM, Hunder GG. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota 1970–1991. Arthritis Rheum 1995; 38: 369–73.
    Direct Link:
  • 20
    Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999; 42: 1259–66.
    Direct Link:
  • 21
    Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000.
  • 22
    Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ III. Incidence of clinically diagnosed vertebral fracdtures: a population-based study in Rochester, Minnesota, 1985–1989. J Bone Miner Res 1990; 7: 332–7.
  • 23
    Madhok R, Melton LJ III, Atkinson EJ, et al. Urban vs rural increase in hip fracture incidence: age and sex of 901 cases 1980-89 in Olmsted County, USA. Acta Orthop Scand 1993; 64: 543–8.
  • 24
    Palumbo PJ, Labarthe DR. The incidence of diabetes mellitus in Rochester, Minnesota, 1945-1969. Adv Metab Dis 1978; 9: 13–28.
  • 25
    Birkhead NC, Wagener HP, Shick RM. Treatment of temporal arteritis with adrenal corticosteroids, results in 55 cases in which the lesion was proved at biopsy. JAMA 1957; 163: 821–7.
  • 26
    Hachulla E, Boivin V, Pasturel-Michon U, Fauchais AL, Bouroz-Joly J, Perez-Cousin M, et al. Prognostic factors and long-term evolution in a cohort of 133 patients with giant cell arteritis. Clin Exp Rheumatol 2001; 19: 171–6.
  • 27
    Nesher G, Sonnenblick M, Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994; 21: 1283–6.
  • 28
    American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39: 1791–1801.
View Full Article (HTML) Get PDF (72K)